Calidi Biotherapeutics Inc (CLDI) recently have taken one step ahead with the beta value of 0.68

Calidi Biotherapeutics Inc (AMEX: CLDI) started the day on Thursday, with a price increase of 6.90% at $1.55, before settling in for the price of $1.45 at the close. Taking a more long-term approach, CLDI posted a 52-week range of $0.73-$26.30.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -50.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 77.06%. This publicly-traded company’s shares outstanding now amounts to $8.08 million, simultaneously with a float of $6.14 million. The organization now has a market capitalization sitting at $18.10 million. At the time of writing, stock’s 50-day Moving Average stood at $1.1432, while the 200-day Moving Average is $3.0343.

Calidi Biotherapeutics Inc (CLDI) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Calidi Biotherapeutics Inc’s current insider ownership accounts for 24.05%, in contrast to 14.45% institutional ownership.

Calidi Biotherapeutics Inc (CLDI) Earnings and Revenue Records

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.

Calidi Biotherapeutics Inc’s EPS increase for this current 12-month fiscal period is 77.06% and is forecasted to reach -0.91 in the upcoming year.

Calidi Biotherapeutics Inc (AMEX: CLDI) Trading Performance Indicators

Let’s observe the current performance indicators for Calidi Biotherapeutics Inc (CLDI). It’s Quick Ratio in the last reported quarter now stands at 0.12. The Stock has managed to achieve an average true range (ATR) of 0.18.

In the same vein, CLDI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -7.16, a figure that is expected to reach -0.86 in the next quarter, and analysts are predicting that it will be -0.91 at the market close of one year from today.

Technical Analysis of Calidi Biotherapeutics Inc (CLDI)

If we take a close look at the recent performances of Calidi Biotherapeutics Inc (AMEX: CLDI), its last 5-days Average volume was 2.15 million that shows progress from its year to date volume of 0.25 million. During the previous 9 days, stock’s Stochastic %D was recorded 89.84% While, its Average True Range was 0.1971.

Raw Stochastic average of Calidi Biotherapeutics Inc (CLDI) in the period of the previous 100 days is set at 55.86%, which indicates a major fall in contrast to 100.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 194.73% that was higher than 111.86% volatility it exhibited in the past 100-days period.